Oral phytic acid-coordinated Prussian blue nanozymes reprogram the intestinal microenvironment for effective treatment of inflammatory bowel disease.
文献摘要
Oral nanozyme therapy is promising for inflammatory bowel disease (IBD), but two issues limit its application: the poor structural and colloidal stability of many nanozymes in the gastrointestinal (GI) tract, and catalytic strategies that address only a single pathological pathway. Phytic acid (PA) was coordinated onto hollow mesoporous Prussian blue nanoparticles (HMPB) in a one-step interfacial reaction to form HMPB-PA. PA coordination increased the hydrodynamic diameter from 144.5 ± 2.4 to 164.4 ± 0.9 nm and shifted the zeta potential from -10.7 ± 0.9 to -23.7 ± 0.3 mV, yielding a negatively charged coordination shell. HMPB-PA retained its number-based hydrodynamic size and most of its catalase (CAT)- and superoxide dismutase (SOD)-like activities in simulated gastric fluid (2 h) and simulated intestinal fluid (36 h). In a dextran sulfate sodium (DSS)-induced colitis model, oral HMPB-PA maintained 97.0% ± 5.1% of baseline body weight (versus 79.9% ± 4.9% for vehicle) and reduced disease activity index and histological damage more effectively than 5-aminosalicylic acid (5-ASA) in this model, while preserving intestinal barrier integrity and microbiota diversity. These results suggest that a single interfacial coordination shell can integrate colloidal stabilization, activity retention, and biological function, offering a physicochemical strategy for gastrointestinally stable oral nanozymes.